Comparison Between Symbicort® and Prednisolone in COPD (SPACE)
A Randomised, Double Blind, Double Dummy, Multicentre Phase III Study Comparing the Efficacy of Budesonide/Formoterol (Symbicort® Forte Turbuhaler®) and Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks, in COPD Patients With an Acute Exacerbation, Followed by Twelve Weeks Open Follow up Period With Budesonide/Formoterol (Symbicort Forte Turbuhaler)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aalbaek, Denmark
- Research Site
-
Aalborg, Denmark
- Research Site
-
Christiansfeld, Denmark
- Research Site
-
Erfurt, Denmark
- Research Site
-
Norager, Denmark
- Research Site
-
Oksbol, Denmark
- Research Site
-
Saeby, Denmark
- Research Site
-
-
-
-
-
Lohja, Finland
- Research Site
-
Pietarsaari, Finland
- Research Site
-
Porvoo, Finland
- Research Site
-
Tammisaari, Finland
- Research Site
-
-
-
-
-
Berlin, Germany
- Research Site
-
Leipzig, Germany
- Research Site
-
Marburg, Germany
- Research Site
-
-
-
-
-
Fredrikstad, Norway
- Research Site
-
Harstad, Norway
- Research Site
-
Molde, Norway
- Research Site
-
Oslo, Norway
- Research Site
-
Straume, Norway
- Research Site
-
-
-
-
-
Akersberga, Sweden
- Research Site
-
Alingsas, Sweden
- Research Site
-
Atvidaberg, Sweden
- Research Site
-
Borlange, Sweden
- Research Site
-
Goteborg, Sweden
- Research Site
-
Hollviken, Sweden
- Research Site
-
Kilafors, Sweden
- Research Site
-
Limhamn, Sweden
- Research Site
-
Lindesberg, Sweden
- Research Site
-
Lulea, Sweden
- Research Site
-
Malmo, Sweden
- Research Site
-
Motala, Sweden
- Research Site
-
Sigtuna, Sweden
- Research Site
-
Stockholm, Sweden
- Research Site
-
Trosa, Sweden
- Research Site
-
Tumba, Sweden
- Research Site
-
Uppsala, Sweden
- Research Site
-
Örebro, Sweden
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with chronic obstructive pulmonary disease and an acute exacerbation
- After the acute treatment a simple pulmonary function test shows a value of 30%-60% of the predicted normal value.
- Patients, who, based on the clinical examination after the initial acute treatment, are candidates for a course of oral steroids for the treatment of acute symptoms due to chronic obstructive pulmonary disease
Exclusion Criteria:
- Diagnosis/history of asthma
- Oxygen uptake (saturation) is <92% after the initial acute treatment
- A requirement for regular use of oxygen therapy
- Regular treatment with any inhaled steroid >1 000 µg/day at study entry
Additional inclusion and exclusion criteria will be evaluated by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Forced Expiratory Volume in one second (FEV1)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Quality of Life
|
|
Number of patients with treatment failures
|
|
Time to first exacerbation
|
|
Number of patients developing an exacerbation
|
|
Diary cards
|
|
- Adverse Events (AEs)
|
|
Serious Adverse Events (SAEs) and Discontinuations due to AEs
|
|
Variables will be assessed before and over the 2+12 weeks treatment period
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Prednisolone
- Budesonide
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- D5892L00002
- Eudra CT 2005-001090-10
- SPACE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.